Monoclonal gammopathy of clinical signifi cance – a group name for dis eases caused by monoclonal immunoglobulin and/ or free light chains. A change in the approach to non-malignant gammopathies
Authors:
Z. Adam 1; Z. Řehák 2; M. Krejčí 1; I. Boichuk 1; L. Pour 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení nukleární medicíny, MOU Brno
2
Published in:
Klin Onkol 2025; 38(5): 336-344
Category:
Reviews
doi:
https://doi.org/10.48095/ccko2025336
Overview
Background: The group of monoclonal gammopathies includes both malignant diseases, such as multiple myeloma and Waldenström‘s macroglobulinemia, and benign proliferations of plasma cells or lymphoplasmacytic cells with the formation of usually low concentrations of monoclonal immunoglobulin and/or free light chains. The term monoclonal gammopathy of undetermined significance (MGUS) is used for conditions with non-malignant proliferation. Aim: In the last 25 years, understanding of the various forms of diseases caused by products of benign lymphoplasmacytic or plasma cell proliferation has significantly increased. The following terms have been used for them: monoclonal gammopathy of renal significance, monoclonal gammopathy of cutaneous significance, monoclonal gammopathy of neurological significance. In the years 2018–2020, the international hematology community accepted the group name monoclonal gammopathy of clinical significance for all conditions in which organ damage is etiopathogenetically related to the products (MGCS) of these cell clones. The text presents an overview of all clinical units that belong to this group and briefly discusses the etiopathogenesis and therapy of these diseases. Conclusion: MGCS is a new term that deserves to be incorporated into the new International Classification of Diseases, which would help improve epidemiological information about these very rare diseases. The same drugs used to treat malignant gammopathies are used in the treatment of MGCS. Patients with MGCS are discriminated, because their diagnoses are not included in the registration studies of new drugs. Therefore, targeted treatment can only be used with the approval of the healthcare payer.
Keywords:
free light chains – monoclonal immunoglobulin – monoclonal gammopathy of undetermined significance – monoclonal gammopathy of clinical significance
Sources
1. Waldenström J. The occurrence of benign, essential monoclonal (M-typ) non makromolecular hyperglobulinemie and it differential diagnosis IV studies in the gammmapathies. Acta Med Scand 1964; 176 : 345–365.
2. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64 (5): 814–826. doi: 10.1016/0002-9343 (78) 90522-3.
3. Englišová M, Englis M. Benign monoclonal hyperglobulinemia. Cas Lek Cesk 1968; 107 (8): 239–240.
4. Špička I, Merta M, Cieslar P et al. Renal impairment in monoclonal gammapathies. Clinical study. Cas Lek Cesk 1995; 134 (15): 478–481.
5. Wohl P, Chadimová M, Engliš M et al. Light chain deposition disease as a cause of renal failure. Cas Lek Cesk 1998; 137 (23): 721–724.
6. Bradwell AR, Carr-Smith HD, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47 (4): 673–680.
7. Dispenzieri A, Katzmann JA, Kyle RA et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375 (9727): 1721–1728. doi: 10.1016/S0140-6736 (10) 60482-5.
8. Merlini G, Stone J. Dangerous small B-cell clones. Blood 2006; 108 (8): 2520–2530. doi: 10.1182/blood-2006-03-001164.
9. Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol 2017; 31 (1): 45–52. doi: 10.1111/jdv. 13847.
10. Claveau JS, Wetter DA, Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J 2022; 12 (4): 58. doi: 10.1038/s41408-022-00661-1.
11. Berk-Krauss J, Rosenbach M. Monoclonal gammopathy of cutaneous significance. J Am Acad Dermatol 2025; 2025: S0190-9622 (25) 02221-2. doi: 10.1016/j.jaad.2025.05.1432.
12. Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120 (22): 4292–4295. doi: 10.1182/blood-2012-07 - 445304.
13. Leung N, Bridoux F, Batuman V et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019; 15 (1): 45–59. doi: 10.1038/s41581-018-0077-4.
14. Amaador K, Peeters H, Minnema MC et al. Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options. Neth J Med 2019; 77 (7): 243–254.
15. Visentin A, Pravato S, Castellani F et al. From biology to treatment of monoclonal gammopathies of neurological significance. Cancers (Basel) 2022; 14 (6): 1562. doi: 10.3390/cancers14061562.
16. Mani AM, Devasia AJ, Nair A et al. Monoclonal gammopathies of “neurological significance”: paraproteinemic neuropathies. Can J Neurol Sci 2021; 48 (5): 616–625. doi: 10.1017/cjn.2020.278.
17. Fermand JP, Bridoux F, Dispenzieri A et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018; 132 (14): 1478–1485. doi: 10.1182/blood-2018-04-839480.
18. Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program 2020; 2020 (1): 380–388. doi: 10.1182/hematology.2020000122.
19. Iberri D, Liedtke M. MGCS: where do we stand today? Hematology Am Soc Hematol Educ Program 2024; 2024 (1): 482–488. doi: 10.1182/hematology.2024000572.
20. Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood 2018; 131 (2): 163–173. doi: 10.1182/blood-2017-09-807560.
21. Sabinot A, Ghetti G, Pradelli L et al. State-of-the-art review on AL amyloidosis in Western Countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev 2023; 59 : 101040. doi: 10.1016/j.blre.2023.101040.
22. Steiner N, Göbel G, Suchecki P et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget 2017; 9 (2): 2344–2356. doi: 10.18632/oncotarget.23412.
23. Jain T, Offord CP, Kyle RA et al. Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica 2013; 98 (10): 1581–1585. doi: 10.3324/haematol.2013.084830.
24. Adam Z, Kment M, Rohál T et al. Poškození ledvin monoklonálním imunoglobulinem a/nebo volnými lehkými řetězci. Klasifikace dle „International Kidney and Monoclonal Gammopathy Research Group“. Trans Hematol Dnes 2025. [In press]. doi: https: //doi.org/10.48095/cctahd2025prolekare.cz7.
25. El Sadaney AO, Dutta A, Cook J et al. Monoclonal Gammopathy of Clinical Significance (MGCS) and related disorders: a review and the role of imaging. Diagnostics (Basel) 2024; 14 (17): 1907. doi: 10.3390/diagnostics14171907.
26. Kastritis E, Palladini G, Minnema MC et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021; 385 (1): 46–58. doi: 10.1056/NEJMoa2028631.
27. Yohannan B, Rees M, Gertz MA et al. Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis. Blood Neoplasia 2025; 2 (2): 100092. doi: 10.1016/j.bneo.2025.100092.
28. Adam Z. Damage caused by monoclonal immunoglobulins and possibilities of therapy. 1. Vnitr Lek 1993; 39 (8): 817–827.
29. Adam Z. Damage caused by monoclonal immunoglobulins and possibilities of therapy. 2. 1993; 39 (10): 1013–1021.
30. Adam Z, Krejčí M, Pour L et al. Změny hemostázy a další poruchy způsobené monoklonálním imunoglobulinem a/nebo volnými lehkými řetězci. Klin Onkol 2025; [in press]. doi: 10.48095/ccko2026001.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2025 Issue 5
Most read in this issue
- Nutrition of patients undergoing haematopoietic stem cell transplantation
- Aktuality z Národního ústavu pro výzkum rakoviny
- Cancer patients admitted to intensive care unit – a six-year retrospective analysis
- Changes in the approach to the analysis and evaluation of inherited pathogenic TP53 variants